Evotec SE Reports Q1-Q3 2024 Financials and Updates
Ticker: EVOTF · Form: 6-K · Filed: Nov 6, 2024 · CIK: 1412558
| Field | Detail |
|---|---|
| Company | Evotec Se (EVOTF) |
| Form Type | 6-K |
| Filed Date | Nov 6, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-results, business-update, foreign-private-issuer
TL;DR
Evotec SE dropped its Q1-Q3 2024 results on Nov 6th. Check the 6-K.
AI Summary
Evotec SE announced its financial results and business updates for the first nine months of 2024 via a press release on November 6, 2024. The company is a foreign private issuer filing a Form 6-K report.
Why It Matters
This filing provides investors with an update on Evotec's financial performance and business activities for the first three quarters of 2024, which can influence investment decisions.
Risk Assessment
Risk Level: low — This is a routine financial reporting filing (6-K) and does not contain new material events or significant financial changes.
Key Players & Entities
- Evotec SE (company) — Registrant
- November 6, 2024 (date) — Date of press release
- 2024 (date) — Reporting period
FAQ
What type of SEC filing is this?
This is a Form 6-K, which is a report of a foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934.
When did Evotec SE file this report?
The filing was made on November 6, 2024.
What is the primary purpose of this 6-K filing?
The filing announces Evotec SE's financial results and business updates for the first nine months of 2024, as detailed in an attached press release (Exhibit 99.1).
Where is Evotec SE headquartered?
Evotec SE is headquartered in Hamburg, Germany.
Does Evotec SE file annual reports under Form 20-F or 40-F?
Yes, Evotec SE indicates it files annual reports under Form 20-F.
Filing Stats: 260 words · 1 min read · ~1 pages · Grade level 14.6 · Accepted 2024-11-06 06:00:16
Filing Documents
- tm2427526d1_6k.htm (6-K) — 10KB
- tm2427526d1_ex99-1.htm (EX-99.1) — 213KB
- tm2427526d1_ex99-2.htm (EX-99.2) — 14KB
- tm2427526d1_ex99-1img001.jpg (GRAPHIC) — 126KB
- tm2427526d1_ex99-1img002.jpg (GRAPHIC) — 4KB
- tm2427526d1_ex99-2img001.jpg (GRAPHIC) — 24KB
- tm2427526d1_ex99-2img002.jpg (GRAPHIC) — 10KB
- 0001104659-24-114462.txt ( ) — 462KB
From the Filing
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2024 COMMISSION FILE NUMBER 001-34041 Evotec SE (Translation of registrant’s name into English) Essener Bogen 7 22419 Hamburg Germany Tel: +49 40 560810 (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F: Form 20-F Form 40-F Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): On November 6, 2024, Evotec SE (the “Company”) issued a press release announcing the Company’s financial results and business updates for the first nine months of 2024 attached hereto as Exhibit 99.1. On November 5, 2024, Evotec SE (the “Company”) announced the Sale of API Manufacturing Facility to Monacum Partners. The Press Release is attached hereto as Exhibit 99.2. EXHIBIT INDEX Exhibit Description of Exhibit 99.1 Evotec SE Interim Statement first nine months 2024 dated November 6, 2024 99.2 Evotec Announces Sale of API Manufacturing Facility to Monacum Partners SIGNATURE Pursuant to the requirements of s the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Evotec SE By: /s/ Laetitia Rouxel Name: Laetitia Rouxel Title: Chief Financial Officer Date: November 6, 2024